Year: 2024

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA,...

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Dr. JD Dudum of Dudum Chiropractic Co-Authors Study Demonstrating the Effectiveness of His Non-Surgical Spinal Decompression Technique

The study demonstrated that nonsurgical spinal decompression improved patient-reported pain intensity, function, and quality of life, offering a viable, non-invasive...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials,...

error: Content is protected !!